| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (I.P.), University of Cincinnati, OH; Department of Neurology (C.F.L.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology (S.S.), Vanderbilt Medical Center, Nashville, TN; and Departments of Neurology and Radiology (R.B.), Partners MS Center, Center for Neurological Imaging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.
Address correspondence and reprint requests to Dr. R. Bakshi, Brigham & Women’s Hospital, Harvard Medical School, 77 Ave. Louis Pasteur, HIM 730, Boston, MA 02115; e-mail: rbakshi{at}bwh.harvard.edu
Gray matter (GM) involvement is detected even in the earliest stages of multiple sclerosis (MS), and GM atrophy occurs at a faster rate than white matter (WM) atrophy early in the disease course. Studies published to date establish that 1) GM involvement and in particular cortical demyelination can be extensive in MS; 2) GM pathology may occur in part independently of WM lesion formation; 3) a primarily GM-related process may be the earliest manifestation of MS; 4) GM involvement is associated with physical disability, fatigue, and cognitive impairment in MS; and 5) GM disease might help explain the observed dissociation between markers of inflammatory demyelination (relapses, WM gadolinium enhancement, WM lesion burden) and disease progression. It remains likely that GM damage is related to WM damage. However, continued studies of GM pathology as well as neuronal and axonal involvement in MS and related experimental models are necessary to better understand the etiology and pathogenesis of the degenerative components.
Disclosure: The authors report no conflicts of interest.
Received January 13, 2006. Accepted in final form September 16, 2006.
This article has been cited by other articles:
|
|
 |
|
  M Calabrese, M Filippi, M Rovaris, V Bernardi, M Atzori, I Mattisi, A Favaretto, P Grossi, L Barachino, L Rinaldi, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study Multiple Sclerosis, January 1, 2009; 15(1): 36 - 41. [Abstract] [PDF]
|
|
|
|
 |
|
 CORRECTION Neurology, December 9, 2008; 71(24): 2021 - 2021. [Full Text] [PDF]
|
|
|
|
|
|
B. A. Cohen Identification, causation, alleviation, and prevention of complications (ICAP): An approach to symptom and disability management in multiple sclerosis Neurology, December 9, 2008; 71(24_suppl_3): S14 - S20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V Nociti, A. Bentivoglio, G Frisullo, A Fasano, F Soleti, R Iorio, G Loria, A. Patanella, A Marti, T Tartaglione, et al. Movement disorders in multiple sclerosis: causal or coincidental association? Multiple Sclerosis, November 1, 2008; 14(9): 1284 - 1287. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Bakshi, M. Neema, B. C. Healy, Z. Liptak, R. A. Betensky, G. J. Buckle, S. A. Gauthier, J. Stankiewicz, D. Meier, S. Egorova, et al. Predicting Clinical Progression in Multiple Sclerosis With the Magnetic Resonance Disease Severity Scale Arch Neurol, November 1, 2008; 65(11): 1449 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Khaleeli, D. R. Altmann, M. Cercignani, O. Ciccarelli, D. H. Miller, and A. J. Thompson Magnetization Transfer Ratio in Gray Matter: A Potential Surrogate Marker for Progression in Early Primary Progressive Multiple Sclerosis Arch Neurol, November 1, 2008; 65(11): 1454 - 1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mesaros, M. Rovaris, E. Pagani, A. Pulizzi, D. Caputo, A. Ghezzi, A. Bertolotto, R. Capra, M. Falautano, V. Martinelli, et al. A Magnetic Resonance Imaging Voxel-Based Morphometry Study of Regional Gray Matter Atrophy in Patients With Benign Multiple Sclerosis Arch Neurol, September 1, 2008; 65(9): 1223 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B Duque, J Sepulcre, B Bejarano, L Samaranch, P Pastor, and P Villoslada Memory decline evolves independently of disease activity in MS Multiple Sclerosis, August 1, 2008; 14(7): 947 - 953. [Abstract] [PDF]
|
|
|
|
|
|
R. Zivadinov, A. T. Reder, M. Filippi, A. Minagar, O. Stuve, H. Lassmann, M. K. Racke, M. G. Dwyer, E. M. Frohman, and O. Khan Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis Neurology, July 8, 2008; 71(2): 136 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Sicotte, K. C. Kern, B. S. Giesser, A. Arshanapalli, A. Schultz, M. Montag, H. Wang, and S. Y. Bookheimer Regional hippocampal atrophy in multiple sclerosis Brain, April 1, 2008; 131(4): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-U. Lee, A. Grigorian, J. Pawling, I-J. Chen, G. Gao, T. Mozaffar, C. McKerlie, and M. Demetriou N-Glycan Processing Deficiency Promotes Spontaneous Inflammatory Demyelination and Neurodegeneration J. Biol. Chem., November 16, 2007; 282(46): 33725 - 33734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zivadinov, B. Weinstock-Guttman, R. Benedict, M. Tamano-Blanco, S. Hussein, N. Abdelrahman, J. Durfee, and M. Ramanathan Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor Hum. Mol. Genet., November 15, 2007; 16(22): 2659 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Houtchens, R.H.B. Benedict, R. Killiany, J. Sharma, Z. Jaisani, B. Singh, B. Weinstock-Guttman, C. R.G. Guttmann, and R. Bakshi Thalamic atrophy and cognition in multiple sclerosis Neurology, September 18, 2007; 69(12): 1213 - 1223. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
